Skip to main content
Erschienen in: Current Allergy and Asthma Reports 1/2012

01.02.2012 | Basic and Applied Science (M Frieri, Section Editor)

Eosinophilic Disorders in Various Diseases

verfasst von: Jocelyn Celestin, Marianne Frieri

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Peripheral and tissue eosinophilia are usually associated with a variety of inflammatory, malignant, and infectious conditions. As the presence of eosinophils in the tissues may cause significant cellular damage to vital organs such as the heart, tissue eosinophilia should be diagnosed and treated promptly. One operative way to evaluate eosinophilic disorders is to classify them into extrinsic and intrinsic. While extrinsic eosinophilic disorders are usually due to the production of eosinopoietic factors derived from T cells or tumor cells, the intrinsic types generally are the result of genetic mutations in the eosinophilic lineage. As we understand more the biology of eosinophils, only a few eosinophilic disorders remain idiopathic. The purpose of this article is to help the clinician classify in an operational manner most eosinophilic disorders, using the extrinsic and intrinsic model. This may facilitate not only a better understanding of the role of eosinophils in these disorders, but also help the systematic clinical work-up and potential treatment of affected patients.
Literatur
1.
Zurück zum Zitat Ehrlich P, Beiträge zur Kenntnis der granulierenden Bindegewebszellen und der eosinophilen Leukocyten. Arch Anat Physiol 1879; 166–169. Ehrlich P, Beiträge zur Kenntnis der granulierenden Bindegewebszellen und der eosinophilen Leukocyten. Arch Anat Physiol 1879; 166–169.
3.
Zurück zum Zitat Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood. 1992;79:3101–9.PubMed Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood. 1992;79:3101–9.PubMed
4.
5.
Zurück zum Zitat Ellis AK, Keith PK. Nonallergic rhinitis with eosinophilia syndrome. Curr Allergy Asthma Res. 2006;6:215–20.CrossRef Ellis AK, Keith PK. Nonallergic rhinitis with eosinophilia syndrome. Curr Allergy Asthma Res. 2006;6:215–20.CrossRef
6.
Zurück zum Zitat Lecki MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet. 2000;356:2144–8.CrossRef Lecki MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet. 2000;356:2144–8.CrossRef
7.
Zurück zum Zitat Apter AJ. Advances in adult asthma diagnosis and treatment and HEDQ in 2010. J Allergy Clin Immunol. 2011;127:116–22.PubMedCrossRef Apter AJ. Advances in adult asthma diagnosis and treatment and HEDQ in 2010. J Allergy Clin Immunol. 2011;127:116–22.PubMedCrossRef
8.
Zurück zum Zitat •Rosenwasser LJ, Rothenberg ME. IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125: 1245–6. This editorial by two well-known authors on the subject substantiates the potential role of anti–IL-5 in the treatment of respiratory conditions associated with eosinophilia. PubMedCrossRef •Rosenwasser LJ, Rothenberg ME. IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125: 1245–6. This editorial by two well-known authors on the subject substantiates the potential role of anti–IL-5 in the treatment of respiratory conditions associated with eosinophilia. PubMedCrossRef
9.
Zurück zum Zitat Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985–93. This article highlights the prednisone sparing effect of anti–IL-5 in patients with asthma and sputum eosinophilia.PubMedCrossRef Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985–93. This article highlights the prednisone sparing effect of anti–IL-5 in patients with asthma and sputum eosinophilia.PubMedCrossRef
10.
Zurück zum Zitat Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmunity Reviews. 2006;5:160–4.PubMedCrossRef Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmunity Reviews. 2006;5:160–4.PubMedCrossRef
11.
Zurück zum Zitat ••Phillips EJ, Chung W-H, Mockenhaupt M et al., Drug hypersensitivity: Pharmacogenetics and clinical syndromes, J Allergy Clin Immunol 2011; 127: S60-6. This article is the latest in a series indicating the role of eosinophils in drug reactions. PubMedCrossRef ••Phillips EJ, Chung W-H, Mockenhaupt M et al., Drug hypersensitivity: Pharmacogenetics and clinical syndromes, J Allergy Clin Immunol 2011; 127: S60-6. This article is the latest in a series indicating the role of eosinophils in drug reactions. PubMedCrossRef
12.
Zurück zum Zitat Kaufman LD, Krupp LB. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol. 1995;25(7):560–7.CrossRef Kaufman LD, Krupp LB. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol. 1995;25(7):560–7.CrossRef
13.
Zurück zum Zitat Nagai Y, Mori T, Abe T, Nomura G. Immediate-type allergy against human insulin associated with type with marked eosinophilia in type 2 diabetic patient. Endocr J. 2001;48:311–6.PubMedCrossRef Nagai Y, Mori T, Abe T, Nomura G. Immediate-type allergy against human insulin associated with type with marked eosinophilia in type 2 diabetic patient. Endocr J. 2001;48:311–6.PubMedCrossRef
14.
Zurück zum Zitat Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the TH1/TH2 cytokine balance toward increased levels of the cytokines and IgE, markers of allergy: a review. Virus Genes. 2006;33:235–52.PubMed Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the TH1/TH2 cytokine balance toward increased levels of the cytokines and IgE, markers of allergy: a review. Virus Genes. 2006;33:235–52.PubMed
15.
Zurück zum Zitat Wilson ME, Weller PF. Eosinophilia. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical infectious diseases: principles, pathogens and practice. Philadelphia: Churchill Livingstone; 2006. p. 1478–95. Wilson ME, Weller PF. Eosinophilia. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical infectious diseases: principles, pathogens and practice. Philadelphia: Churchill Livingstone; 2006. p. 1478–95.
16.
Zurück zum Zitat Saubolle MA, McKellar PP, Sussland D. Epidemiologic, clinical, and diagnostic aspects of coccidioidomycosis. J Clin Microbiol. 2007;45(1):26–30.PubMedCrossRef Saubolle MA, McKellar PP, Sussland D. Epidemiologic, clinical, and diagnostic aspects of coccidioidomycosis. J Clin Microbiol. 2007;45(1):26–30.PubMedCrossRef
17.
Zurück zum Zitat Frieri M, Akkina S, Anand P. A case of persistent eosinophilia in lupus nephritis. Ann Allergy Asthma Immunol. 2011;107:P108. Frieri M, Akkina S, Anand P. A case of persistent eosinophilia in lupus nephritis. Ann Allergy Asthma Immunol. 2011;107:P108.
18.
Zurück zum Zitat Simon HU, Seger R. Hyper-IgE syndrome associated with an IL-4-producing γ/δ + T-cell clone. J Allergy Clin Immunol. 2007;119:246–8.PubMedCrossRef Simon HU, Seger R. Hyper-IgE syndrome associated with an IL-4-producing γ/δ + T-cell clone. J Allergy Clin Immunol. 2007;119:246–8.PubMedCrossRef
19.
Zurück zum Zitat Schaffer JV. The changing face of graft-versus-host disease. Semin Cutan Med Surg. 2006;25:190–200.PubMedCrossRef Schaffer JV. The changing face of graft-versus-host disease. Semin Cutan Med Surg. 2006;25:190–200.PubMedCrossRef
20.
Zurück zum Zitat Jacobsohn DA, Schechter T, Seshadri R, et al. Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. Transplantation. 2004;77:1096–100.PubMedCrossRef Jacobsohn DA, Schechter T, Seshadri R, et al. Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. Transplantation. 2004;77:1096–100.PubMedCrossRef
21.
Zurück zum Zitat Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol. 2004;77(1):82–5.PubMedCrossRef Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol. 2004;77(1):82–5.PubMedCrossRef
22.
Zurück zum Zitat Frieri M. Mastocytosis, Chapter 14. Humana Press, 2009. Frieri M. Mastocytosis, Chapter 14. Humana Press, 2009.
23.
Zurück zum Zitat Shahzad G, Mustacchia P, Frieri M. Role of mucosal inflammation in eosinophilic esophagitis: Review of the literature, International Scholarly Research Network (ISRN) Gastroenterology, vol. 2011, Article ID 468073, 7pages, 2011. Shahzad G, Mustacchia P, Frieri M. Role of mucosal inflammation in eosinophilic esophagitis: Review of the literature, International Scholarly Research Network (ISRN) Gastroenterology, vol. 2011, Article ID 468073, 7pages, 2011.
24.
Zurück zum Zitat ••Liacouras CA, Furuta GT, Hirano I, Atkins D et al., Eosinophilic esophagitis: Updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011; 128: 3–20. This article is a comprehensive review of the latest about the etiology, pathogenesis, and treatment of EE. PubMedCrossRef ••Liacouras CA, Furuta GT, Hirano I, Atkins D et al., Eosinophilic esophagitis: Updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011; 128: 3–20. This article is a comprehensive review of the latest about the etiology, pathogenesis, and treatment of EE. PubMedCrossRef
25.
Zurück zum Zitat Stein ML, Collins MH, Villanueva JM, et al. Anti-interleukin-5(mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2007;118:1312–9.CrossRef Stein ML, Collins MH, Villanueva JM, et al. Anti-interleukin-5(mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2007;118:1312–9.CrossRef
26.
Zurück zum Zitat Blanchard N, Wang KF, Stringer, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest. 2006;116(2):536–47.PubMedCrossRef Blanchard N, Wang KF, Stringer, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest. 2006;116(2):536–47.PubMedCrossRef
27.
Zurück zum Zitat Arora S, Yamazaki K. Eosinophilic esophagitis: asthma of the esophagus? Clin Gastroenterol Hepatol. 2004;2(7):523–30.PubMedCrossRef Arora S, Yamazaki K. Eosinophilic esophagitis: asthma of the esophagus? Clin Gastroenterol Hepatol. 2004;2(7):523–30.PubMedCrossRef
28.
Zurück zum Zitat Rothenberg ME. Biology and treatment of eosinophilic esophagitis. Gastroenterology. 2009;137(4):1238–49.PubMedCrossRef Rothenberg ME. Biology and treatment of eosinophilic esophagitis. Gastroenterology. 2009;137(4):1238–49.PubMedCrossRef
29.
Zurück zum Zitat Knight K, Blázquez AB, Zhang S, Mayer L, Sampson HA, Berin MC. CD4 T cells activated in the mesenteric lymph node mediate gastrointestinal food allergy in mice. Am J Physiol. 2007;293(6):G1234–43. Knight K, Blázquez AB, Zhang S, Mayer L, Sampson HA, Berin MC. CD4 T cells activated in the mesenteric lymph node mediate gastrointestinal food allergy in mice. Am J Physiol. 2007;293(6):G1234–43.
30.
Zurück zum Zitat Rothenberg ME: Eosinophilic Gastroenteropathies. In Middleton’s Allergy Principles and Practice. Edited by Adkinson FN, Busse WW, Bochner BS et al. (eds), Elsevier; 2008: 879–891. Rothenberg ME: Eosinophilic Gastroenteropathies. In Middleton’s Allergy Principles and Practice. Edited by Adkinson FN, Busse WW, Bochner BS et al. (eds), Elsevier; 2008: 879–891.
31.
Zurück zum Zitat Foroughi S, Prussin C. Clinical management of eosinophilic gastrointestinal disorders. Curr Allergy Asthma Rep. 2005;5:259–61.PubMedCrossRef Foroughi S, Prussin C. Clinical management of eosinophilic gastrointestinal disorders. Curr Allergy Asthma Rep. 2005;5:259–61.PubMedCrossRef
32.
Zurück zum Zitat Campos LE, Pereira LF. Pulmonary eosinophilia. J Bras Pneumol. 2009;35(6):561–73 Campos LE, Pereira LF. Pulmonary eosinophilia. J Bras Pneumol. 2009;35(6):561–73
33.
Zurück zum Zitat Allen JN, Magro CM, King MA. The eosinophilic pneumonias. Semin Respir Crit Care Med. 2002; Apr;23(2):127–34. Allen JN, Magro CM, King MA. The eosinophilic pneumonias. Semin Respir Crit Care Med. 2002; Apr;23(2):127–34.
34.
Zurück zum Zitat Alam M, Burki NK. Chronic eosinophilic pneumonia: a review. South Med J. 2007 Jan;100(1):49–53 Alam M, Burki NK. Chronic eosinophilic pneumonia: a review. South Med J. 2007 Jan;100(1):49–53
35.
Zurück zum Zitat Ionescu MA, Rivet J, Daneshpouy M, et al. In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia. J Am Acad Dermatol. 2005;52:32–9.PubMedCrossRef Ionescu MA, Rivet J, Daneshpouy M, et al. In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia. J Am Acad Dermatol. 2005;52:32–9.PubMedCrossRef
36.
Zurück zum Zitat Samoszuk M, Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin’s disease with eosinophilia. Blood. 1990;75:13–6.PubMed Samoszuk M, Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin’s disease with eosinophilia. Blood. 1990;75:13–6.PubMed
37.
Zurück zum Zitat Cordovi, MV, Verma, V, Gotlieb V Frieri M. Lymphocyte rich Hodgkin’s lymphoma presented with warm hemolytic anemia. a case report and literature review. Case Reports in Hematology, 2011. Cordovi, MV, Verma, V, Gotlieb V Frieri M. Lymphocyte rich Hodgkin’s lymphoma presented with warm hemolytic anemia. a case report and literature review. Case Reports in Hematology, 2011.
38.
Zurück zum Zitat Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndrome. Allergy. 2004;59:673–89.PubMedCrossRef Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndrome. Allergy. 2004;59:673–89.PubMedCrossRef
39.
Zurück zum Zitat Gotlib J, Cross NCP, Gilliland DG. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol. 2006;3:535–69.CrossRef Gotlib J, Cross NCP, Gilliland DG. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol. 2006;3:535–69.CrossRef
40.
Zurück zum Zitat Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukemias. Br J Haematol. 2003;122:173–9.PubMedCrossRef Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukemias. Br J Haematol. 2003;122:173–9.PubMedCrossRef
41.
Zurück zum Zitat Keung YK, Beaty M, Steward W, et al. Chronic myelocitic leukemia with eosinophilia, t(9,12)(q34;p13) and ETV6-ABL gene rearrangement: case report and review of the literature. Cancer Genet Cytogenet. 2002;138:139–42.PubMedCrossRef Keung YK, Beaty M, Steward W, et al. Chronic myelocitic leukemia with eosinophilia, t(9,12)(q34;p13) and ETV6-ABL gene rearrangement: case report and review of the literature. Cancer Genet Cytogenet. 2002;138:139–42.PubMedCrossRef
42.
Zurück zum Zitat Chang HW, Leong KH, Koh DR, et al. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood. 1999;93:1651–7.PubMed Chang HW, Leong KH, Koh DR, et al. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood. 1999;93:1651–7.PubMed
43.
Zurück zum Zitat Fletcher S, Bain B. Eosinophilic leukaemia. Br Med Bull. 2007;81–2:115–27.CrossRef Fletcher S, Bain B. Eosinophilic leukaemia. Br Med Bull. 2007;81–2:115–27.CrossRef
44.
Zurück zum Zitat Weller PF: Eosinophilia and Eosinophil-Related Disorders. In: Middleton’s Allergy Principles and Practice. Edited by Adkinson FN, Busse WW, Bochner BS et al. Elsevier; 2008: 859–877. Weller PF: Eosinophilia and Eosinophil-Related Disorders. In: Middleton’s Allergy Principles and Practice. Edited by Adkinson FN, Busse WW, Bochner BS et al. Elsevier; 2008: 859–877.
45.
Zurück zum Zitat Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes as a therapeutic target for imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201–14.PubMedCrossRef Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes as a therapeutic target for imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201–14.PubMedCrossRef
46.
Zurück zum Zitat Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol. 2005;114(1):52–60.PubMedCrossRef Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol. 2005;114(1):52–60.PubMedCrossRef
47.
Zurück zum Zitat Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101(12):4714–6.PubMedCrossRef Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101(12):4714–6.PubMedCrossRef
48.
Zurück zum Zitat Jain N, Cortes J, Quintas-Cardama A, et al. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res. 2009;33(6):837–9.PubMedCrossRef Jain N, Cortes J, Quintas-Cardama A, et al. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res. 2009;33(6):837–9.PubMedCrossRef
49.
Zurück zum Zitat Nand R, Bryke C, Kroft SH, et al. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosin kinase inhibitors. Leuk Res. 2009;33(8):1144–6.PubMedCrossRef Nand R, Bryke C, Kroft SH, et al. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosin kinase inhibitors. Leuk Res. 2009;33(8):1144–6.PubMedCrossRef
50.
Zurück zum Zitat Newberry AM, Williams DN, Stauffer WM, et al. Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis. Chest. 2005;128:3681–4.PubMedCrossRef Newberry AM, Williams DN, Stauffer WM, et al. Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis. Chest. 2005;128:3681–4.PubMedCrossRef
Metadaten
Titel
Eosinophilic Disorders in Various Diseases
verfasst von
Jocelyn Celestin
Marianne Frieri
Publikationsdatum
01.02.2012
Verlag
Current Science Inc.
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 1/2012
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-011-0240-5

Weitere Artikel der Ausgabe 1/2012

Current Allergy and Asthma Reports 1/2012 Zur Ausgabe

Anaphylaxis and Drug Allergy (P Lieberman and S Spector, Section Editors)

Mediators Released During Human Anaphylaxis

Anaphylaxis and Drug Allergy (P Lieberman and S Spector, Section Editors)

Latitude, Sunlight, Vitamin D, and Childhood Food Allergy/Anaphylaxis

Anaphylaxis and Drug Allergy (P Lieberman and S Spector, Section Editors)

The Likelihood of Remission of Food Allergy in Children: When Is the Optimal Time for Challenge?

Anaphylaxis and Drug Allergy (P Lieberman and S Spector, Section Editors)

Therapeutics in Food Allergy: The Current State of the Art

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.